Cover Image

De-escalation of adjuvant chemotherapy for HER2 negative breast cancer

Saved in:

Bibliographic Details
Main Authors:	Dr Alicia FC Okines (Author), Dr Marina Parton (Author)
Format:	Book
Published:	Elsevier, 2021-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Escalation of adjuvant endocrine therapy for early hormone-dependent HER2-negative breast cancer: to whom, when and why?
by: I. V. Kolyadina
Published: (2024)

De-Escalation of Surgical Treatment after Neoadjuvant Chemotherapy in Breast Cancer Patients
by: Gianluca Franceschini, et al.
Published: (2024)

Clinical and morphological aspects of neoadjuvant chemotherapy efficacy in patients with aggressive luminal HER2-negative breast cancer
by: D. A. Morozov, et al.
Published: (2022)

ADJUVANT CHEMOTHERAPY OF PRIMARY OPERABLE LUMINAL B BREAST CANCER WITHOUT OVEREXPRESSION OF HER2/NEU IN POSTMENOPAUSAL WOMEN: YES OR NO?
by: Yu. S. Shatova, et al.
Published: (2017)

Real-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer
by: Maria Fernanda Imperio Pereira, et al.
Published: (2024)

Serum levels of VEGF and MCSF in HER2+ / HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
by: Roberto J. Arai, et al.
Published: (2018)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
by: Hao Tian, et al.
Published: (2021)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
by: Xueqiong Xun, et al.
Published: (2023)

Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
by: Li S, et al.
Published: (2018)

Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients
by: Ovidiu Balacescu, et al.
Published: (2016)

High Cytoplasmic CXCR4 Expression Predicts Prolonged Survival in Triple-Negative Breast Cancer Patients Treated with Adjuvant Chemotherapy
by: Bobae Shim, et al.
Published: (2018)

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
by: Abdel-Razeq H, et al.
Published: (2022)

The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status
by: Sanaa Gamrani, et al.
Published: (2023)

Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
by: Anne Julienne Genuino, et al.
Published: (2019)

PREVENTION AND MONITORING OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER
by: N. A. Kozyavin, et al.
Published: (2018)

The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer
by: Mirosława Püsküllüoğlu, et al.
Published: (2024)

Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence
by: Wedad H. Alotaibi, et al.
Published: (2022)

Adjuvant chemotherapy of megestrol acetate in advanced breast cancer: A meta-analysis
by: Yanping Shui, et al.
Published: (2015)

Efficacy and safety of goserelin combined with adjuvant chemotherapy in premenopausal women with breast cancer
by: Yang Wang, et al.
Published: (2015)

Chlorin Conjugates in Photodynamic Chemotherapy for Triple-Negative Breast Cancer
by: Meden F. Isaac-Lam
Published: (2024)

Her-2 neu negative lipid rich breast carcinoma in an immunocompromised patient
by: Deepika Sirohi, M.D, et al.
Published: (2015)

Variations in the body mass index in Brazilian women undergoing adjuvant chemotherapy for breast cancer
by: Marcos Desídérío Ricci, et al.
Published: (2014)

Results of combination treatment using docetaxel in an adjuvant chemotherapy regimen for resectable breast cancer
by: L. V. Bolotina, et al.
Published: (2014)

Application of dynamic magnetic resonance imaging information technology in adjuvant chemotherapy for breast cancer
by: Caixian Yang, et al.
Published: (2020)

Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel
by: Sreenath M. Krishnan, et al.
Published: (2021)

Hormone Receptor Positive/HER2 Negative Breast Cancer With Isolated Bladder Metastasis: A Rare Case
by: Noman Ahmed Jang Khan MD, et al.
Published: (2021)

PHARMACOECONOMIC EVALUATION OF RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF HR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER
by: N. A. Avksentyev, et al.
Published: (2018)

Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
by: Hui Kong, et al.
Published: (2022)

The role of carboplatin in the neoadjuvant chemotherapy treatment of triple negative breast cancer
by: Aurelio Bartolome Castrellon, et al.
Published: (2017)

Targeted EV to Deliver Chemotherapy to Treat Triple-Negative Breast Cancers
by: Yingnan Si, et al.
Published: (2022)

Antibiotic De-Escalation in Critically Ill Patients with Negative Clinical Cultures
by: Spencer Roper, et al.
Published: (2023)

The prognosis of patients treated with everolimus for advanced ER‐positive, HER2‐negative breast cancer is driven by molecular features
by: Hélène Salaün, et al.
Published: (2024)

Anti-metastatic and anti-proliferative activity of eugenol against triple negative and HER2 positive breast cancer cells
by: Mashan L. Abdullah, et al.
Published: (2018)

A longitudinal study on the changes in the self‐efficacy of breast cancer patients during adjuvant chemotherapy
by: Chiao‐Chi Kuan, et al.
Published: (2023)

Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life
by: Palumbo R, et al.
Published: (2015)

Chemotherapy adjuvant and chemotherapy-induced neutropenia
by: Yiu-Tai Li, et al.
Published: (2022)

Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
by: Milana Bergamino Sirvén, et al.
Published: (2019)

<i>FGFR1</i> Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer
by: María Gaibar, et al.
Published: (2022)

COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017)

Educational Case: HER-2 Positive Breast Cancer
by: Julia Jennings MD, et al.
Published: (2021)